

**The Value Of Tumour Markers CA 125,
TAG 72-3 And Urinary Plasminogen
Activator In Ovarian Neoplasms**

A Thesis

**Submitted for the partial fulfillment of
MD Degree In Obstetrics and Gynecology**

By

WAEEL MAHMOUD MOHAMMAD

Assistant Lecturer in Obstetrics and Gynecology,
Faculty of Medicine, Ain Shams University

Under The Supervision of

PROF. DR. HAMDI MOHAMMAD EL KABARITY

Professor of Obstetrics and Gynecology
Faculty of Medicine, Ain Shams University

PROF. DR. IBRAHIM YASSIN ABOU SENNA

Professor of Obstetrics and Gynecology
Faculty of Medicine, Ain Shams University

PROF. DR. HAZEM AMIN EL ZENEINY

Professor of Obstetrics and Gynecology
Faculty of Medicine, Ain Shams University

PROF. DR. ALI KHALIFA ALI

Professor of Biochemistry and Head of Oncology Diagnostic Unit.
Faculty of Medicine, Ain Shams University

**Faculty Of Medicine
Ain Shams University**

1998





"قالوا سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم الحكيم"

بسم الله
العظيم



To My Family,

The Whole And

The Nucleus

CONTENTS

Page

Acknowledgements	
List of Tables	
List of Figures	
List of Abbreviations	
Introduction and Aim of The Work	1
Review of Literature	
I Ovarian Neoplasms	3
II Tumor Markers in Ovarian Cancer	29
III The Coagulation System and Fibrinolysis	36
IV Cancer Antigen 125 (CA 125)	69
V Tumor Associated Glycoprotein 72-3 (TAG 72-3)	81
Patients and Methods	91
Results	105
Discussion	159
Summary and Conclusion	173
References	176
Arabic Summary	

LIST OF TABLES

No	Title	Page
1	The FIGO stage grouping for primary carcinoma of the ovary (1985).	26
2	The pathology of benign ovarian lesions.	105
3	The pathology of malignant ovarian neoplasms.	107
4	The distribution of histopathological types and grades among the malignant ovarian tumors.	109
5	Range and mean of age among the patients with benign ovarian lesions and malignant ovarian neoplasms.	110
6	Range and mean of parity among patients with benign ovarian lesions and malignant ovarian neoplasms.	110
7	The reproductive state among patients with benign ovarian lesions and malignant ovarian neoplasms.	110
8	Surgical staging of patients with malignant ovarian tumors.	111
9	State of lymph nodes during laparotomy among patients with malignant ovarian tumors.	111
10	The results of cytoreduction operation among patients with malignant ovarian tumors.	111
11	The results of cytoreduction operation to surgical staging.	114
12	The results of cytoreduction operation to tumor pathology.	114
13	Descriptive statistics of CA 125 in the different groups.	115
14	Descriptive statistics of CA 72.4 in the different groups.	115
15	Descriptive statistics of u-PA in the different groups.	116
16	Comparison of the sensitivities of CA 125, CA 72.4 and u-PA, Fixing the specificity at 95%.	116
17	Calculation of the cut-off values of CA 125, CA 72.4 and u-PA.	116
18	Comparison of the mean values of CA 125, CA 72.4 and u-PA in the control, benign and malignant groups.	120
19	The sensitivity, specificity, positive and negative predictive values of CA 125 at different cut-off values.	120
20	The sensitivity, specificity, positive and negative predictive values of CA 72.4 at different cut-off values.	121
21	The sensitivity, specificity, positive and negative predictive values of u-PA at different cut-off values.	121

No	Title	Page
22	The combined sensitivity, specificity, positive and negative predictive values of CA 125 and CA 72.4 (SP-MP).	125
23	The combined sensitivity, specificity, positive and negative predictive values of CA 125 and CA 72.4 (TP-MP).	125
24	The combined sensitivity, specificity, positive and negative predictive values of CA 125, CA 72.4 and u-PA (SP-MP).	125
25	The combined sensitivity, specificity, positive and negative predictive values of CA 125, CA 72.4 and u-PA (TP-MP).	125
26	The association between CA 125 and patient's age.	126
27	The association between CA 125 and patient's parity.	126
28	The association between CA 125 and reproductive state.	127
29	The distribution of CA 125 in the different histopathological subtypes.	127
30	The association between CA 125 and tumor stages.	127
31	The association between CA 125 and histopathological grade.	128
32	The association between CA 125 and tumor residuals.	128
33	The association between CA 125 and lymph nodes status.	129
34	The association between CA 72.4 and patient's age.	130
35	The association between CA 72.4 and patient's parity.	130
36	The association between CA 72.4 and reproductive state.	130
37	The distribution of CA 72.4 in the different histopathological subtypes.	130
38	The association between CA 72.4 and tumor stages.	131
39	The association between CA 72.4 and histopathological grade.	131
40	The association between CA 72.4 and tumor residuals.	132
41	The association between CA 72.4 and lymph nodes status.	132
42	The association between u-PA and patient's age.	133
43	The association between u-PA and patients parity.	133
44	The association between u-PA and reproductive state.	134
45	The distribution of u-PA in the different histopathological subtypes.	134
46	The association between u-PA and tumor stages.	134
47	The association between u-PA and histopathological grade.	135
48	The association between u-PA and tumor residuals.	135

No	Title	Page
49	The association between u-PA and lymph nodes status.	135
50	The association between the panel of markers and patient's age (SP-MP).	136
51	The association between the panel of markers and patient's age (TP-MP).	136
52	The association between the panel of markers and patient's parity (SP-MP).	137
53	The association between the panel of markers and patients parity (TP-MP).	137
54	The association between the panel of markers and reproductive state (SP-MP).	137
55	The association between the panel of markers and reproductive state (TP-MP).	138
56	The association between the panel of markers and tumor stages (SP-MP).	138
57	The association between the panel of markers and tumor stages (TP-MP).	138
58	The association between the panel of markers and histopathological grade (SP-MP).	139
59	The association between the panel of markers and histopathological grade (TP-MP).	139
60	The association between the panel of markers and tumor residuals (SP-MP).	139
61	The association between the panel of markers and tumor residuals (TP-MP).	140
62	The association between the panel of markers and lymph nodes status (SP-MP).	140
63	The association between the panel of markers and lymph nodes status (TP-MP).	140
64	The association between u-PA and CA 72.4.	141
65	The association between u-PA and CA 125.	141
66	The association between CA 72.4 and CA 125.	141
67	The mean duration of follow-up for patients with malignant ovarian tumors.	142
68	The clinical and histopathological features of patients with poor prognostic outcome.	142
69	The association between CA 125 and prognosis of patients with malignant ovarian neoplasms.	143

No	Title	Page
70	The association between CA 72.4 and prognosis of patients with malignant ovarian neoplasms.	144
71	The association between u-PA and prognosis of patients with malignant ovarian neoplasms.	144
72	The association between the panel of markers and prognosis of patients with malignant ovarian neoplasms (SP-MP).	144
73	The association between the panel of markers and prognosis of patients with malignant ovarian neoplasms (TP-MP).	145
74	The association between patient's age and prognosis.	145
75	The association between parity and patient's prognosis.	145
76	The association between reproductive state and patients prognosis.	146
77	The association between tumor relapse and prognosis in patients with malignant ovarian tumors.	146
78	The association between patients prognosis and survival.	147
79	The association between surgical staging and patients prognosis.	147
80	The association between histopathological grading and patient's prognosis.	148
81	The association between tumor residual and patients prognosis.	148
82	The association between lymph nodes metastases and patients prognosis.	149
83	The association between tumor relapse and patient survival.	149
84	The association between CA 125 and tumor relapse in patients with malignant ovarian neoplasms.	150
85	The association between CA 125 and patient survival in patients with malignant ovarian neoplasms.	150
86	The association between CA 72.4 and tumor relapse in patients with malignant ovarian neoplasms.	151
87	The association between CA 72.4 and patient survival in patients with malignant ovarian neoplasms.	151
88	The association between u-PA and tumor relapse in patients with malignant ovarian neoplasms.	151
89	The association between u-PA and patient survival in patients with malignant ovarian neoplasms.	152

No	Title	Page
90	The association between the panel of markers and tumor relapse in patients with malignant ovarian neoplasms (SP-MP).	152
91	The association between the panel of markers and tumor relapse in patients with malignant ovarian neoplasms (TP-MP).	152
92	The association between the panel of markers and patients survival in patients with malignant ovarian neoplasms (SP-MP).	153
93	The association between the panel of markers and patient survival in patients with malignant ovarian neoplasms (TP-MP).	153
94	The association between patients age and tumor relapse.	154
95	The association between the reproductive state and tumor relapse.	154
96	The association between patient's parity and tumor relapse.	154
97	The association between the tumor grade and relapse.	155
98	The association between the tumor grade and patients survival.	155
99	The association between surgical staging and tumor relapse.	156
100	The association between surgical staging and patients survival.	156
101	The association between lymph nodes metastases and tumor relapse.	157
102	The association between lymph nodes metastases and patients survival.	157
103	The association between tumor residuals after cytoreduction and tumor relapse.	158
104	The association between tumor residuals after cytoreduction and patients survival.	158

LIST OF FIGURES

No	Title	Page
1	The coagulation cascade.	38
2	The structural and functional relationships among protein components of hemostasis.	40
3	Schematic presentation of the fibrinolytic system.	42
4	Standard curve for protein.	100
5	The pathology of benign ovarian lesions.	106
6	The pathology of malignant ovarian neoplasms.	108
7	Surgical staging of patients with malignant ovarian tumors.	112
8	The results of cytoreduction operations among patients with malignant ovarian tumors.	113
9	The distribution of CA 125 in the different groups.	117
10	The distribution of CA 72.4 in the different groups.	118
11	The distribution of u-PA in the different groups.	119
12	The Receiver Operator Characteristic (ROC) curve for CA 125.	122
13	The Receiver Operator Characteristic (ROC) curve for CA 72.4.	123
14	The Receiver Operator Characteristic (ROC) curve for u-PA.	124

LIST OF ABBREVIATIONS

AFP	Alpha Feto Protein
AgNORs	Nucleolar Organizing Regions
AML	Acute Myeloid Leukemia
APSAC	Anisoylated Plasminogen Streptokinase Activator Complex (Anistreplase)
Arg	Arginine
BRCA-1	Breast Cancer Antigen-1
CASA	Cancer Associated Serum Antigen
cDNA	Complementary DNA
CEA	Carcino Embryonic Antigen
CML	Chronic Myeloid Leukemia
CSF	Colony-Stimulating Factor
DIC	Disseminated Intravascular Coagulation
ECM	Extra Cellular Matrix
EGF	Epidermal Growth Factor
ELISA	Enzyme Linked ImmunoSorbant Assay
FIGO	Federation Internationale de Gynecologie et d'Obstetrique
GGT	Gamma-Glutamyl Transpeptidase
Glu	Glutamine
GTP	Guanosine Triphosphate
hCG	Human Chorionic Gonadotrophin
HK	High molecular-weight Kininogen
HMFG	Human Milk Fat Globule protein
HMWtc- UK	High Molecular Weight Two Chain Urokinase
HNPCC	Hereditary Nonpolyposis Colon Cancer
Ile	Isoleucin
INF	Interferon
IRMA	Immuno RadioMetric Assay
kDa	Kilo Dalton
LASA,LSA	Lipid Associated Sialic Acid
LDH	Lactate Dehydrogenase
LIA	Luminometric Immuno Assay
LMP	Low Malignant Potential
LMWtc-UK	Low Molecular Weight Two Chain Urokinase
LNS	Lymph Nodes
LOH	Loss Of Heterozygosity
Lys	Lysine

Mab	Monoclonal Antibody
MCSF	Macrophage Colony-Stimulating Factor
MEIA	Microparticle Enzyme Immunoassay
Mw	Molecular Weight
P	Level of Significance
P ³²	Radio Phosphorus
PAI	Plasminogen Activator Inhibitor
PDGF	Platelet-Derived Growth Factor
PEM	Polymorphic Epithelial Mucinous ovarian antigens
PI	Pulsatility index
PLAP	Placental Alkaline Phosphatase
PN-1	Protease Nexin-1
Pro-MMPs	Promatrix Metalloproteinases
Pro-UK	Prourokinase
Rb	Retinoblastoma
rscu-PA	Recombinant Single-Chain Urinary Plasminogen Activator (Saruplase)
rt-PA	Recombinant t-PA (Alteplase)
sct-PA	Single Chain Tissue Plasminogen Activator
scu-PA	Single Chain Urokinase-type Plasminogen Activator
SD	Standard Deviation
SK	Streptokinase
SLX	Sialyl Lex-I
SP-MP	Subtotally Positive Marker Panel
STAR	Recombinant Staphylokinase
TATI	Tumor Associated Trypsin Inhibitor
tct-PA	Two Chain Tissue Plasminogen Activator
TNF	Tumor Necrosis Factor
t-PA	Tissue Plasminogen Activator
TP-MP	Totally Positive Marker Panel
TPS	Tissue Polypeptide Specific Antigen
UGP	Urinary Gonadotrophin Fragments
u-PA	Urinary Plasminogen Activator
u-PAR	Urinary Plasminogen Activator Receptor
US	Ultrasonography
Val	Valine
WHO	World Health Organization
X	Mean
X ²	Chi Square

ACKNOWLEDGMENTS

I am greatly indebted to my supervisor Prof. Dr. *Hamdi El Rabarity*, Professor of Obstetrics and Gynecology, Ain Shams University, who allowed me to pursue this topic, supervised the study and continued to offer help far beyond the call of duty.

Likewise, I am deeply indebted to Prof. Dr. *Ibrahim Abou Senna*, Professor of Obstetrics and Gynecology, Ain Shams University, for his kind supervision, tremendous assistance, continuous guidance and enthusiastic support.

I wish to express my deepest gratitude and sincere appreciation to Prof. Dr. *Hazem El Zeneiny*, Professor of Obstetrics and Gynecology, Ain Shams University, for offering me much of his time and experience throughout the whole work.

I am deeply grateful to Prof. Dr. *Ali Khalifa* Professor of Biochemistry and Head of the Oncology Diagnostic Unit, Ain Shams University and the Godfather of tumor markers in Egypt, for his support, unforgettable assistance, encouragement, help and much more.

I cannot also forget to offer my thanks to the member staff of The Early Cancer Detection Unit (Department of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University) and The Oncology Diagnostic Unit (Faculty of Medicine, Ain Shams University), for their tremendous help during the laboratory part of this work. A special thanks goes to Prof Dr. *Sanaa Eissa*, Prof. Dr. *Magda Abdel Salam*

and Dr. Mahmoud AbdelWahab for their effective efforts and help.

In research, one does not only need the assistance of one's superiors, but also the help of one's family. As such, I must bow in respect to my parents, my wife and my daughters for their tolerant support throughout this work.

At last, but not least, my heart felt thanks to all the patients participated in this work, I wish it would be of benefit for all the patients in the future.

Marl Mahmoud Mohammad
(El Sewify)
Cairo, 1998.